GLP-1 vs Tirzepatide Dosing: Clinical Equivalency Guide

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide and tirzepatide are not interchangeable at equivalent doses. Tirzepatide activates both GLP-1 and GIP receptors, making it approximately 2–3 times more potent than semaglutide for weight management and metabolic improvement. Direct dose conversion depends on individual factors, not a simple formula.

Choosing between these medications involves more than dosage arithmetic. Genetic predispositions in GLP1R, GIPR, and metabolic genes, combined with biomarker profiles and clinical history, can help providers tailor selection. PlexusDx supports this precision-wellness approach with actionable genetic insights.

Potency Differences: Why Tirzepatide and Semaglutide Aren't Directly Comparable

Tirzepatide is a dual agonist; semaglutide is a GLP-1-only agonist. This mechanistic difference drives potency. Tirzepatide's dual action on GLP-1 and GIP receptors amplifies glucose control, satiety signaling, and metabolic rate suppression relative to semaglutide alone.

Clinical trials show tirzepatide 10 mg approaches or exceeds semaglutide 2.4 mg in weight loss and glycemic benefit. However, individual responses vary significantly based on receptor sensitivity, baseline metabolic state, and genetic factors. Dosing should always be guided by a qualified healthcare provider, not by direct conversion.

Clinical Potency Comparison and Dosing Framework

The table below summarizes approximate potency relationships and typical dosing ranges. Note that these are clinical observations, not prescribing equivalencies. Final dose selection depends on individual tolerance, response, and provider judgment.

Metric	Semaglutide (GLP-1 only)	Tirzepatide (GLP-1/GIP dual)
Typical max dose	2.4 mg weekly	15 mg weekly
Relative potency estimate	Baseline (1x)	2–3x higher for weight loss
Onset of satiety	3–5 days post-injection	2–4 days post-injection
Average weight loss at max dose	10–15% body weight	20–22% body weight

Biomarker and Genetic Context for Medication Selection

Individual variations in peptide receptor expression and metabolic gene function influence medication responsiveness. Genetic variants in GLP1R, GIPR, FTO, and MC4R pathways may help predict whether a patient benefits more from single or dual agonism. These predispositions should inform provider discussions.

Biomarkers such as fasting insulin, inflammatory markers, and lipid profiles provide additional context. A patient with high baseline insulin resistance may respond more dramatically to tirzepatide's dual action, while another with normal insulin sensitivity might achieve results with semaglutide alone. Genetic insights can help providers make more tailored recommendations.

Safety, Eligibility, and Provider-Guided Selection

Both medications carry similar gastrointestinal side effects (nausea, vomiting, diarrhea) and pancreatitis risk. Tirzepatide's higher potency may increase initial GI tolerability challenges in some patients. Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2.

Selection should rest on clinical evaluation, not dosage assumptions. Patients with prior adverse reactions to GLP-1 agonists, severe renal impairment, or unstable mental health conditions require careful assessment. A qualified provider can review your medical history, genetic insights, and goals to guide appropriate medication and titration strategy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test identifies predispositions in peptide receptor and metabolic pathways relevant to GLP-1 and tirzepatide response. Variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) may help provide context for how your physiology aligns with single versus dual agonist mechanisms. This information should be interpreted with a qualified healthcare provider.

The genetic test reveals predispositions in peptide-pathway signaling, not exact medication response or efficacy prediction. For example, certain GLP1R variants correlate with baseline receptor sensitivity, but do not determine whether tirzepatide will outperform semaglutide for your specific circumstances. Genetics is one data point among clinical history, biomarkers, and trial-and-error response.

Combining genetic insights with your provider's clinical judgment creates a more informed personalization strategy. Rather than guessing at dose equivalency or switching medications by trial, genetic context can support a conversation about which mechanism and starting dose align best with your metabolic profile and health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.